NCT03817528View on ClinicalTrials.gov

ITI-007 (Lumateperone Tosylate) for Schizophrenia

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

September 23, 2020

Study Completion Date

September 23, 2020

Conditions
Schizophrenia
Interventions
DRUG

ITI-007

ITI-007 (Lumateperone tosylate)dosed 40-60 mg based on efficacy/adverse events

Trial Locations (1)

10032

New York State Psychiatric Institute, New York

Sponsors
All Listed Sponsors
collaborator

Intra-Cellular Therapies, Inc.

INDUSTRY

lead

New York State Psychiatric Institute

OTHER